CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for S1 Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

S1 Biopharma Inc
46Th Floor
Phone: (201) 839-0941p:201 839-0941 NEW YORK, NY  10007  United States
S1 Biopharma Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-199111) with the SEC on 6/25/2015.
This company is no longer actively traded on any major stock exchange.
Business Summary
S1 Biopharma, Inc. (S1 Biopharma) is engaged in the development of first-in-class drugs for the treatment of sexual dysfunction in both women and men. The company’s non-hormonal therapies work by restoring the natural balance of neurotransmitters in the brain. The Company’s product pipeline includes Lorexys, Orexa, S1B-307 and S1B-3006. The scientific basis for the development of these drugs is the Kinsey dual control model. The Company’s lead product is Lorexys which is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in women. Orexa is being developed for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in men. S1B-307 is under development for the treatment of female sexual arousal disorder (FSAD) and female orgasmic disorder (FOD). S1B-3006 is under development for the treatment of resistant sexual dysfunction conditions.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201412/31/2013YesYes-Yes-

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Nicolas G.Sitchon 40
Chief Financial Officer John F.Kaufmann 38 1/1/2012 1/1/2012
Chief Medical Officer Robert E.Pyke 72 1/1/2012 1/1/2012
Director Jane H.Hollingsworth 56 8/1/2014 8/1/2014
Director Anthony G.Lapointe 55 8/1/2014 8/1/2014

General Information
Number of Employees: 4 (As of 9/30/2014)
Outstanding Shares: 10,876,080 (As of 12/16/2014)
Stock Exchange: NASD
Federal Tax Id: 273629427


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023